Similarly, the compound ND-654 inhibits the development of HCC by inhibiting acetyl-CoA carboxylase (ACC, for de novo synthesis of fatty acids), another classic substrate of AMPK.21 Not surprisingly, efforts have been made to develop pharmacological agonists that directly target AMPK for potential efficacy in treating HCC. Here, PRKAA2 is linked to hepatocellular carcinoma.